Introduced Legislation to Expand Home Infusions for Medicare Patients with Rare Genetic Disease: Introduced the John W. Walsh Alpha-1 Home Infusion Act. This bill will allow Medicare beneficiaries with alpha-1 antitrypsin deficiency to receive essential treatments at home, reducing healthcare costs and enhancing their quality of life.
Expand home infusions for Medicare patients with alpha-1 antitrypsin deficiency.
Occurrences
Evidence
legacy_unverified · Source version not recorded · locator unknown
Sponsor: Rep. Salazar, Maria Elvira [R-FL-27] (Introduced 03/25/2025) ... Latest Action: House - 03/25/2025 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means ... Tracker: Tip | This bill has the status Introduced ... This bill provides for Medicare coverage of treatment for alpha-1 antitrypsin (AAT) deficiency ... coverage of at-home augmentation therapy for beneficiaries with emphysema as a result of severe hereditary AAT deficiency.
legacy_unverified · Source version not recorded · locator unknown
Congress.gov identifies Rep. Maria Elvira Salazar as the sponsor of H.R.2343, introduced 03/25/2025. The latest action is House referral to Energy and Commerce and Ways and Means on 03/25/2025, and the tracker says the bill has the status Introduced. The page lists only one actions overview item, introduced in House, and summarizes the bill as providing Medicare coverage of at-home augmentation therapy for beneficiaries with emphysema from severe hereditary AAT deficiency.
legacy_unverified · Source version not recorded · locator unknown
CMS describes the existing Medicare home infusion therapy benefit as created by Section 5012 of the 21st Century Cures Act and effective January 1, 2021, for home infusion therapy-associated professional services for certain drugs and biologicals administered intravenously or subcutaneously through a DME pump. CMS separately notes a 2023 appropriations provision for home IVIG items and services for primary immune deficiency diseases.
Assessments
Salazar materially attempted the promise by sponsoring H.R.2343, the John W. Walsh Alpha-1 Home Infusion Act of 2025, to create Medicare coverage for at-home augmentation therapy for eligible alpha-1 antitrypsin deficiency patients. However, the official bill status remains Introduced with only committee referrals and no House passage, Senate passage, enactment, or CMS implementation of the specific Alpha-1 Medicare home-infusion expansion. Existing CMS home-infusion authorities cover other categories and do not deliver this promised Alpha-1 expansion.
Salazar made a serious federal legislative attempt by sponsoring H.R.2343, the John W. Walsh Alpha-1 Home Infusion Act of 2025, which would provide Medicare coverage for at-home augmentation therapy for qualifying alpha-1 antitrypsin deficiency patients. However, as of the official Congress.gov record checked on May 8, 2026, the bill remains only introduced and referred to House committees, with no passage, enactment, or implemented Medicare coverage expansion. Because the promised policy outcome has not been delivered, but she did materially advance it through sponsorship, this is a failed delivery with an effort badge.